DeepMed Research

Mabwell (Shanghai) Bioscience Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2017-05-12

Employees: 1.4K

Market Cap: -

Website: https://www.mabwell.com

Clinical Trials

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Solid Tumors

Interventions: Drug: 9MW2821
Drug: Other anti-cancer therapy

First Posted Date: 2025-04-27

Last Posted Date: 2025-04-27

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 188

Registration Number: NCT06947226

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

Phase 1

Not yet recruiting

Conditions: Gynecological Malignancies

Interventions: Drug: 9MW2821+other anticancer therapy

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 260

Registration Number: NCT06926998

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Phase 1

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: bulumtatug fuvedotin

First Posted Date: 2025-04-03

Last Posted Date: 2025-04-03

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT06908928

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Urothelial Carcinoma Bladder
Urothelial Carcinoma Recurrent
Urothelial Carcinoma of the Renal Pelvis and Ureter

Interventions: Drug: 9MW2821
Drug: Toripalimab (JS001 )

First Posted Date: 2025-02-12

Last Posted Date: 2025-03-21

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT06823427

Locations: 🇨🇳
Hunan Tumor Hospital, Changsha, Hunan, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China

A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis

Phase 3

Recruiting

Conditions: Postmenopausal Women Osteoporosis

Interventions: Drug: 9MW0311
Drug: Prolia®

First Posted Date: 2025-02-03

Last Posted Date: 2025-02-03

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 278

Registration Number: NCT06804590

Locations: 🇨🇳
Mabwell (Shanghai) Bioscience Co., Ltd., Beijing, China

A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

Phase 1

Recruiting

Conditions: Beta-Thalassemia

Interventions: Drug: 9MW3011
Drug: 9MW3011 placebo

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 40

Registration Number: NCT06772766

Locations: 🇨🇳
The first Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳
Hainan General Hospital, Haikou, Hainan, China

A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Phase 1

Recruiting

Conditions: Polycythemia Vera

Interventions: Drug: 9MW3011

First Posted Date: 2024-12-31

Last Posted Date: 2025-05-11

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 108

Registration Number: NCT06752746

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

and more 3 locations

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: 9MW2821
Drug: Chemotherapy

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-22

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 420

Registration Number: NCT06692166

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Phase 3

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: 9MW2821
Drug: Gemcitabine
Drug: Toripalimab
Drug: Cisplatin/Carboplatin

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT06592326

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: 9MW2821
Drug: PD-1 inhibitior

First Posted Date: 2024-07-09

Last Posted Date: 2025-01-10

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 160

Registration Number: NCT06492005

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy